Lupin Pharmaceuticals, Inc. Receives US FDA Approval For Sertraline

BALTIMORE, Feb. 7 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Sertraline Hydrochloride Tablets, 25mg, 50mg and 100mg. Commercial shipments of the product have commenced.

Lupin's Sertraline Tablets are the AB-rated generic equivalent of Pfizer's Zoloft(R) Tablets, indicated for the treatment of major depressive disorder. The brand product had annual sales of approximately $2.1 billion for the twelve months ended December 2006, based on IMS sales data.

This is Lupin's 18th ANDA approval by the US FDA to date.

About Lupin

Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with a strong research focus. It has a program for developing New Chemical Entities. The Company has a state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDs and Asthma.

For the nine-month period ended December 2006, the Company's Revenues and Profit after Tax were Rs.14,985 million (US$ 335 million) and Rs.1,650 million (US$ 37 million) respectively. Please visit for more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top five Pharmaceutical companies in India. Through its sales and marketing headquarters in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines trusted by healthcare professionals and patients across geographies. For more information, visit

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.

*Zoloft(R) is a registered trademark of Pfizer Pharmaceuticals. For More Information: Contact: Edith St-Hilaire Senior Marketing Manager 410-576-2000

Lupin Pharmaceuticals, Inc.

CONTACT: Edith St-Hilaire, Senior Marketing Manager, LupinPharmaceuticals, +1-410-576-2000

Back to news